Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $41.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective hoisted by The Goldman Sachs Group from $36.00 to $41.00 in a research report report published on Friday,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities analysts have also issued reports on TARS. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Tarsus Pharmaceuticals currently has an average rating of “Buy” and an average price target of $54.20.

Tarsus Pharmaceuticals Stock Performance

TARS stock opened at $44.83 on Friday. The firm has a market cap of $1.71 billion, a PE ratio of -11.77 and a beta of 1.00. The company has a current ratio of 5.42, a quick ratio of 6.99 and a debt-to-equity ratio of 0.30. The stock has a 50-day moving average price of $37.84 and a 200-day moving average price of $32.53. Tarsus Pharmaceuticals has a 1-year low of $15.60 and a 1-year high of $52.99.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TARS. Geode Capital Management LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 835,790 shares of the company’s stock valued at $27,494,000 after purchasing an additional 62,555 shares in the last quarter. Barclays PLC grew its position in Tarsus Pharmaceuticals by 345.9% in the 3rd quarter. Barclays PLC now owns 98,663 shares of the company’s stock worth $3,246,000 after purchasing an additional 76,538 shares in the last quarter. Wellington Management Group LLP grew its position in Tarsus Pharmaceuticals by 14.2% in the 3rd quarter. Wellington Management Group LLP now owns 145,347 shares of the company’s stock worth $4,780,000 after purchasing an additional 18,019 shares in the last quarter. Ikarian Capital LLC lifted its position in shares of Tarsus Pharmaceuticals by 28.7% during the 3rd quarter. Ikarian Capital LLC now owns 1,030,277 shares of the company’s stock worth $33,886,000 after buying an additional 230,000 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $763,000. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.